DDrare: Database of Drug Development for Rare Diseases

Other: natalizumab discontinuation (DrugBank: Natalizumab)

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02775110 (ClinicalTrials.gov)	November 2012	29/12/2015	Natalizumab Temporary Discontinuation Study	Natalizumab Temporary Discontinuation Study	Multiple Sclerosis	Other: Natalizumab discontinuation	University at Buffalo	NULL	Completed	18 Years	65 Years	Both	50	Phase 4	United States